It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Stem cells undergo cellular division during their differentiation to produce daughter cells with a new cellular identity. However, the epigenetic events and molecular mechanisms occurring between consecutive cell divisions have been insufficiently studied due to technical limitations. Here, using the FUCCI reporter we developed a cell-cycle synchronised human pluripotent stem cell (hPSC) differentiation system for uncovering epigenome and transcriptome dynamics during the first two divisions leading to definitive endoderm. We observed that transcription of key differentiation markers occurs before cell division, while chromatin accessibility analyses revealed the early inhibition of alternative cell fates. We found that Activator protein-1 members controlled by p38/MAPK signalling are necessary for inducing endoderm while blocking cell fate shifting toward mesoderm, and that enhancers are rapidly established and decommissioned between different cell divisions. Our study has practical biomedical utility for producing hPSC-derived patient-specific cell types since p38/MAPK induction increased the differentiation efficiency of insulin-producing pancreatic beta-cells.
Many stem cells exhibit cell division coupled to differentiation, though the changes occurring between consecutive cell divisions have been difficult to study. Here they use synchronized hPSC culture to show that production of transcription factors and epigenetic changes are linked with cell division timing.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details






1 University of Cambridge, Department of Surgery, Cambridge, UK (GRID:grid.5335.0) (ISNI:0000000121885934); Wellcome Genome Campus, Wellcome Sanger Institute, Hinxton, UK (GRID:grid.52788.30) (ISNI:0000 0004 0427 7672); University of Cambridge, Wellcome – MRC Cambridge Stem Cell Institute, Cambridge, UK (GRID:grid.5335.0) (ISNI:0000000121885934); European Bioinformatics Institute, European Molecular Biology Laboratory, Hinxton, UK (GRID:grid.225360.0) (ISNI:0000 0000 9709 7726)
2 University of Oxford, Headington, Botnar Research Centre, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, Old Road, Oxford, UK (GRID:grid.4991.5) (ISNI:0000 0004 1936 8948)
3 University of Cambridge, Department of Surgery, Cambridge, UK (GRID:grid.5335.0) (ISNI:0000000121885934); The Francis Crick Institute, London, UK (GRID:grid.451388.3) (ISNI:0000 0004 1795 1830)
4 University of Cambridge, Department of Surgery, Cambridge, UK (GRID:grid.5335.0) (ISNI:0000000121885934)